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Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies
cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the
emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the
majority of patients develop RAS mutations, while a subset acquires EGFR extracellular
domain (ECD) mutations. Here we find that patients who experience greater and longer
responses to EGFR blockade preferentially develop EGFR ECD mutations, while RASmutations
emerge more frequently in patients with smaller tumour shrinkage and shorter progression-
free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR
antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not
EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade.
These data indicate that clonal evolution of drug-resistant cells is associated with the clinical
outcome of CRC patients treated with anti-EGFR antibodies.
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H
uman tumours such as colorectal, lung and breast cancers
are thought to evolve through expansion of clonal waves
driven by the acquisition of genomic alterations1,2.
Tumour progression is fuelled by genomic instability, which
sustains the continuous emergence of new genetic variants that
are then fixed in the population by selective pressures not yet
completely understood3.
Genomic instability and clonal evolution result in widespread
cellular heterogeneity, which allows human cancers to survive
pressures exerted by drugs designed to target oncogenic
dependencies4,5. The intrinsic ability of subclonal cell
populations to evolve when challenged with anticancer agents is
arguably the major limitation to further progress in the medical
treatment of oncological patients.
In colorectal cancers the limitations imposed by the emergence
of drug resistance are manifest during treatment with the anti-
EGFR antibodies cetuximab or panitumumab. In this setting,
remarkable clinical responses can be observed, which are
invariably followed by tumour progression and relapse6,7.
Acquired resistance to EGFR blockade is driven by the
emergence of KRAS/NRAS mutations or the development of
EGFR extracellular domain (ECD) variants, which impair
antibody binding8,9. Studies in clinical specimens indicate that
RAS mutations are detected more frequently than EGFR ECD
mutations in samples of patients that relapse on EGFR
blockade10–12. Considering that EGFR ECD mutations
completely abrogate the interaction with anti-EGFR monoclonal
antibodies, it is unclear why only a fraction of relapsed tumours
display these alterations. Furthermore, whether and how the
emergence of RAS or EGFR ECD mutations impacts the clinical
development of patients receiving cetuximab or panitumumab is
presently undefined. We find that clonal evolution during the
acquisition of resistance impacts the clinical response to anti-
EGFR therapy in colorectal cancer, and this may be influenced by
the subclonal mutational landscape and environmental pressure
on the tumour.
Results
Acquired RAS or EGFR mutations and anti-EGFR response.
We considered whether the emergence of distinct resistance
mechanisms might affect the clinical outcome of metastatic col-
orectal cancer (CRC) patients treated with anti-EGFR antibodies.
To test this hypothesis, we examined the clinical characteristics of
27 individuals who initially responded but developed either RAS
(KRAS/NRAS) or EGFR ECD mutations at progression during
treatment with cetuximab or panitumumab (Table 1 and
Supplementary Tables 1 and 2). No associations were found
between mutations at acquired resistance (RAS versus EGFR) and
clinico-pathological characteristics of the patients.
However, the mutational profile at the time of progression was
correlated with the clinical outcome, defined as initial complete
response, partial response or stable disease for more than 16
weeks, as assessed by Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1. Mutations in RAS were detected in
20 patients and mutations in EGFR ECD in 14 patients. The
co-occurrence of RAS and EGFR ECD mutations was detected in
7 of these cases (Table 1 and Supplementary Table 2). We found
that the emergence of RAS or EGFR ECD mutations correlated
with clinical response. Namely, most patients who achieved stable
disease as best response developed RAS mutations, whereas
patients with partial response preferentially showed EGFR ECD
mutations, either with or without RAS, in their tumours (Fig. 1a).
Most notably, a clear distinction was observed when progression-
free survival (PFS) was used to stratify patients who developed
only RAS or EGFR ECD mutations. Median PFS for the EGFR
group was 44.6 weeks (95% confidence interval (CI), 38–49)
versus 25.6 weeks (95% CI, 24–27) for the RAS group, hazard
ratio 2.56 (95% CI, 1.06–6.21; P¼ 0.013 by a stratified log-rank
test) (Fig. 1b). These findings suggest that CRC patients who
develop RAS mutations on EGFR blockade achieve reduced
tumour shrinkage and shorter duration of response than patients
in which EGFR ECD mutations emerge during therapy.
RAS and EGFR dynamics in ctDNA during EGFR blockade.
The clinical results described above suggest that RAS and EGFR
ECD mutations are correlated with the extent of tumour
shrinkage and duration of response in CRC patients treated with
anti-EGFR antibodies. We postulated that this reflected the
dynamics of clonal evolution of RAS and EGFR ECD mutant cells
during treatment. To test this we studied the molecular profile of
circulating cell-free tumour DNA (ctDNA), an approach we have
previously exploited to identify and monitor resistance to targeted
therapies in CRC patients13. We therefore analysed liquid
biopsies of CRC patients who developed resistance to EGFR
blockade. Within our clinical database, we identified three
patients in which RAS and EGFR ECD mutations were
concomitantly present in ctDNA collected at progression and
for which longitudinal samples had been collected. Molecular
profiling on blood draws obtained at different time points during
treatment revealed that RAS mutant clones, which were
undetectable when therapy was initiated, became evident earlier
than EGFR ECD variants (Fig. 2). Owing to the limitations of
liquid biopsies, it cannot be determined if the mutations occur in
the same cell.
Evolution of mutations in CRC cells during EGFR blockade.
The differential impact of RAS and EGFR ECD mutations on PFS
and the dynamics observed in liquid biopsies suggest that
colorectal tumours evolve along distinct molecular trajectories
according to the occurrence of specific resistance mutations.
To gather insights into the molecular roots of these findings,
we used two CRC cell models (LIM1215 and OXCO-2) both of
which are sensitive to EGFR blockade and amenable to the
analysis of individual subclones. LIM1215 and OXCO-2 cells
were treated continuously with cetuximab for several months; at
the end of the treatment, the presence of RAS and EGFR ECD
mutations was assessed using droplet digital PCR (ddPCR). When
compared with the parental (sensitive) counterpart, resistant cell
populations displayed KRAS, NRAS or, less frequently, EGFR
ECD mutations11 (Supplementary Fig. 1). To study the molecular
characteristics of resistant clones, we performed limiting cell
dilutions followed by DNA sequencing. This analysis retrieved
clones carrying concomitantly both NRAS and EGFR ECD
mutations (Supplementary Fig. 1).
To gain further insights into the clonal dynamics leading to the
expansion of clones carrying single or multiple resistance alleles,
LIM1215 cells were genetically tracked with a lentiviral library of
B50 million unique molecular barcodes consisting of two 18 base
pair (bp) random DNA sequences (Supplementary Fig. 2). The
progeny of individually barcoded cells can be later identified by
the corresponding barcode sequence. The primer region flanking
the barcode sequence allows for the amplification of the barcode
from genomic DNA (gDNA) that can then be deconvoluted using
next-generation sequencing (NGS) analysis14,15 (Supplementary
Table 3). A barcoded population of one million cells was treated
with cetuximab for B6 months. An equal number of cells were
set aside for gDNA analysis as the representative baseline. As the
cells underwent treatment with the anti-EGFR antibody, samples
of the cell populations were collected at regular intervals and, at
the end, all samples were analysed (Fig. 3). This analysis revealed
that a clone with an NRAS G12C mutation rapidly became
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predominant in the population while the heterogeneity decreased
as indicated by barcode analysis in Supplementary Fig. 3. After
2 months, another clone, labelled with a different barcode and
carrying the EGFR S492R mutation, started to emerge. Limiting
dilution assays showed that this clone carried both the NRAS
G12C and the EGFR S492R mutation (Supplementary Fig. 3).
The EGFR variant clone increased in subsequent time points,
and when the experiment was terminated (6 months from start),
the EGFR S492R mutant clone became dominant (Fig. 3 and
Supplementary Fig. 3).
Fitness analysis of RAS and EGFR ECD mutant clones. To
provide mechanistic support for these data, drug sensitivity
measurements were performed on cell populations and clones
Table 1 | Clinical characteristics of colorectal cancer patients with secondary resistance to anti-EGFR based therapy and
emergence of RAS and/or EGFR ECD mutations.
All (N¼ 27) EGFR only (N¼ 7) RAS only (N¼ 13) EGFRþRAS (N¼ 7)
Male sex (%) 13 (48) 5 (71) 6 (46) 2 (29)
Age (median, range) 60 (31–81) 64 (44–78) 59 (42–81) 55 (31–78)
Primary tumour site
Right 5 (18%) 2 (29%) 1 (8%) 2 (29%)
Left and rectum 21 (78%) 4 (57%) 12 (92%) 5 (71%)
Unknown 1 (4%) 1 (14%) 0 0
Anti-EGFR drug
Cetuximab 23 (85%) 6 (86%) 11 (85%) 6 (86%)
Panitumumab 4 (15%) 1 (14%) 2 (15%) 1 (14%)
Chemotherapy
Irinotecan-based 20 (74%) 4 (57%) 10 (77%) 6 (86%)
Oxaliplatin-based 4 (15%) 2 (29%) 1 (8%) 1 (14%)
None 3 (11%) 1 (14%) 2 (15%) 0
Line of treatment
1st 5 (19%) 2 (29%) 1 (8%) 2 (29%)
2nd 9 (33%) 2 (29%) 6 (46%) 1 (14%)
Z3rd 13 (48%) 3 (42%) 6 (46%) 4 (57%)
Best response
Stable disease 416 weeks 12 (44%) 1 (14%) 8 (62%) 3 (43%)
Response 15 (56%) 6 (86%) 5 (38%) 4 (57%)
Progression-free survival
Median (weeks, 95% CI) 39.1 (33–46) 45 (42–48) 25.6 (24–27) 38.7 (21–56)
All patients had an initial response to treatment, defined as complete response, partial response or stable disease 416 weeks, and then progressed.
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Figure 1 | Clinical benefit of CRC patients treated with anti-EGFR therapy according to the emergence of EGFR ECD versus RAS mutations.
(a) Response measured by RECISTcriteria 1.1 in 27 CRC patients, according to the emergence of EGFR ECD versus RASmutations detected in tumour tissue
and/or plasma. Most patients with emergence of EGFR ECD mutations achieved a partial response, whereas patients with emergence of RAS mutations
mostly had stable disease as best response (P¼0.128 by Fisher’s exact test). Cases with co-existence of EGFR ECD and RASmutations were excluded from
the group of RAS mutant tumours (RAS group) and included in the group of EGFR ECD mutant tumours (EGFR group). (b) Kaplan–Meier estimates of PFS
according to the emergence of RAS mutations versus EGFR ECD mutations detected in tumour tissue and/or plasma. The hazard ratio for the RAS group
(grey line) as compared with the EGFR group (red line) was 2.56 (95% CI, 1.06–6.21; P¼0.013 by a stratified log-rank test). Median PFS time in the RAS
group was 25.6 weeks (95% CI, 24–27), as compared with 44.6 weeks (95% CI, 38–49) in the EGFR group.
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carrying the NRAS only or EGFR mutations. The results indicate
that cells harbouring mutant EGFR had increased fitness as
compared with the single (NRAS) mutant cells when drug
pressure was applied (Fig. 4a). To further corroborate these
findings, we performed clonogenic assays in the presence of
cetuximab that confirmed that the EGFR mutant cells displayed
increased fitness when challenged with anti-EGFR antibodies
(Supplementary Fig. 4). To understand how the presence of single
or dual mutations impacted the EGFR–RAS signalling pathway,
we performed biochemical analyses. These experiments revealed
that in the presence of cetuximab, ERK activation (measured by
phosphorylation) is partially reduced in NRAS mutant cells as
compared with untreated cells; while in cells carrying both NRAS
and EGFR mutations, ERK activation is not affected by the
addition of cetuximab (Fig. 4b). This is likely related to the
inability of cetuximab to bind the receptor. These results indicate
that the occurrence of NRAS mutations alone or in combination
with EGFR ECD mutations differentially affects the EGFR-RAS
signalling pathway.
The subclonal landscape of CRC affects drug resistance. The
data described in Table 1 and Fig. 1 suggest that the pre-existence
of subclones carrying RAS but not EGFR ECD mutations affects
the clinical outcome of CRC patients treated with cetuximab
or panitumumab. Furthermore, liquid biopsies and functional
analyses of cell populations support the possibility that RAS
mutant clones emerge before EGFR ECD variants. We reasoned
that these findings might be mechanistically explained if cells
carrying RAS mutations were latently present in colorectal
tumours before exposition to EGFR blockade. Specifically,
we hypothesized that RAS pathway mutations (but not EGFR
ECD variants) might emerge in colorectal tumours in response
to ‘environmental’ stress. We therefore contemplated which
conditions might affect the emergence of RAS mutant subclones
in otherwise wild-type (WT) CRC cell populations.
We previously reported that CRC cells sensitive to EGFR
blockade are dependent on EGFR ligands16. We therefore
postulated that reduced access to growth factors and nutrients
may represent a stress condition leading to the emergence of RAS
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Figure 2 | Longitudinal analysis of plasma ctDNA collected during anti-EGFR therapy. Shades of black and grey indicate frequency of circulating RAS
mutant alleles; and shades of red and orange indicate frequency of circulating EGFR mutant alleles. All patients achieved partial response or disease
stabilization under EGFR blockade administered alone or in combination with standard chemotherapy. RAS mutant clones are apparent in the circulation
months earlier than EGFR clones in all of the three cases. CT, computed tomography; PD, progressive disease; Pmab, panitumumab; PR, partial response;
SD, stable disease.
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pathway mutations17,18. Moreover, as patients often receive anti-
EGFR antibodies after or concomitantly with chemotherapy19, we
wanted to assess if this could affect the clonal composition of
colorectal tumours. To test these possibilities, we used LIM1215
cells. As previously reported, high-sensitivity genotyping using
ddPCR detected very low levels of RAS mutations in LIM1215
cells that were never exposed to anti-EGFR antibodies (Fig. 5 and
ref. 20). Notably, the same approach did not reveal the presence
of EGFR ECD mutations (Fig. 5), even when an average
sensitivity of 0.005% was achieved (Supplementary Table 4).
These results are aligned with our previous data demonstrating
that in both microsatellite stable (MSS) and microsatellite
instability (MSI) CRC cell lines EGFR ECD mutations are never
detected before administration of anti-EGFR treatment11.
To corroborate our observations, when sufficient material was
available, a more sensitive molecular analysis was performed also
on patients’ tissue samples obtained at baseline. All patient
samples were RASWT using the standard of care assays; however,
using a sensitive NGS-based technique, it was found that four
of the patients indeed had pre-existing RAS mutations
(Supplementary Table 1). These mutations were confirmed by
competitive allele-specific TaqMan PCR. Notably, the same
mutations detected at baseline were also detected at progression
(Supplementary Tables 1 and 2). No EGFR ECD mutations were
detected at baseline. The clinical and preclinical results are
consistent with other studies of CRC tumour samples from
patients that were never exposed to anti-EGFR antibodies as it
has been demonstrated that they may carry subclonal RAS
mutations but not pre-existing EGFR ECD mutations10,12,21.
We then cultured LIM1215 CRC cells in the presence of
reduced serum conditions (1% fetal bovine serum; FBS) for
4 months and used ddPCR to measure the presence of RAS and
EGFR mutations. Notably, when LIM1215 cells were cultured in
low-serum conditions, the levels of KRAS and NRAS mutations
increased, while EGFR ECD mutations were not detected (Fig. 5).
While MSI cellular models have inherent limitations, they often
recapitulate the mechanisms of resistance to targeted therapy that
were observed in clinical specimens. For example, the emergence
of RAS mutations on EGFR blockade in CRC patients was
correctly predicted by experiments performed in MSI cell lines as
we previously reported20. Furthermore, subclonal RAS mutant
cells were detected in the LIM1215 cell line before anti-EGFR
treatment similarly to what has been found in patients that were
never exposed to anti-EGFR antibodies12.
To test whether chemotherapy affected the emergence of RAS
or EGFR ECD mutations, we treated LIM1215 cells with FOLFIRI
(5FUþ irinotecan) alone or in combination with cetuximab.
To parallel the chemotherapy schedule administered to patients,
cells were treated with FOLFIRI for four cycles of 2 days each
(each cycle was repeated every 2 weeks and was separated from
the next one by 12 days). At the end of the fourth cycle of
chemotherapy, cells were allowed to repopulate in the absence of
drugs, and growing cells were then collected. RAS or EGFR ECD
mutations did not emerge in cells treated with FOLFIRI alone,
while the FOLFIRIþ cetuximab-treated cells displayed RAS and
EGFR ECD mutations, as also observed in cells treated with
cetuximab alone (LIM1215 R1 and R5) (Fig. 5). These results are
in concordance with what has been observed in patient samples
regarding the lack of emergence of KRAS mutations after
chemotherapy treatment20.
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Discussion
The emergence of drug resistance is arguably the major limitation
to the development of effective targeted therapies. Genes
encoding for protein and lipid kinases are frequently altered in
cancer and can be pharmacologically inhibited. Accordingly,
a large number of kinases have been targeted with remarkable,
albeit often transitory, effect in several cancer types22. In the last
10 years, the molecular mechanisms of resistance to kinase
inhibitors have been elucidated in details in multiple tumour
types. Generally, clones carrying mutations or other genetic
alterations, which confer an advantage in the presence of the
inhibitor, drive resistance. The innate genomic instability of
cancers can contribute to this process23. For example, acquired
mutations in the catalytic domain of the receptor tyrosine kinase
cKIT limit the effectiveness of the kinase inhibitor imatinib in
gastrointestinal stromal tumours24. In other settings, resistance
can arise not only through alterations that affect the drug target
but also through activation of alternative pathways8,25. For
example, the EGFR T790M variant emerges frequently in NSCLC
carrying EGFR mutations that are treated with erlotinib or
gefitinib26. However, lung cancer cells can also become resistant by
constitutive activation of parallel pathways exemplified by MET
amplification27. Similarly, colorectal tumours that are treated with
anti-EGFR antibodies develop resistance through three main
mechanisms: mutations in the antibody-binding site (such as the
EGFR ECD variants)10,11; activation of alternative pathways28,29; or
reactivation of downstream signalling (such as KRAS or NRAS
mutations)30. As mentioned above, the acquisition of drug-
resistance mutations can be affected by the genomic instability
of cancer. For example, in colorectal cancers, MSI can impact
the acquisition of mutations31,32. New information is emerging
suggesting that gDNA containing oncogenic mutations, which can
also contribute to resistance, can be found in exosomes33,34 and
these could be the means for horizontal mutant gene transfer35.
Using CRC as a model system, we report that—from a clinical
perspective—mutations that confer resistance to EGFR blockade
are not created equal. Notably, we provide evidence that patients
who experience more profound and longer responses to EGFR
blockade preferentially develop EGFR ECD mutations, while RAS
mutations emerge more frequently in patients with limited
tumour shrinkage and shorter PFS. Intrigued by these clinical
observations, we exploited populations of cancer cells to study
clonal evolution during EGFR blockade. Our findings support a
model in which RAS pathway mutations are selected under
distinct environmental ‘stress’ (such as reduced access to growth
factors and nutrients, but not to chemotherapy agents) as they
confer a growth advantage in these conditions. Under the same
circumstances, EGFR ECD mutations do not provide a survival
advantage and are positively selected only when the cells are
challenged with anti-EGFR antibodies. These results, albeit
limited to the cell lines we studied, support a model whereby
cells carrying RAS mutations are latently present (that is,
pre-exist) in WT CRC populations sensitive to EGFR blockade
and rapidly expand under anti-EGFR drug pressure.
Clinically, this could translate into smaller tumour shrinkage
and earlier progression on anti-EGFR treatment in patients.
Differently, EGFR ECD mutant subclones do not pre-exist in WT
CRC but emerge during drug-driven tumour evolution and
confer a fitness advantage throughout anti-EGFR treatment. This
translates into more profound tumour responses and longer time
to anti-EGFR treatment failure in patients who preferentially
develop EGFR ECD mutations. These results are aligned with
previous reports that CRC cell lines may contain pre-existing but
low levels of RAS mutations, but they can also acquire mutations
de novo20. This would apply to the acquisition of mutations in the
EGFR ECD during anti-EGFR therapy as there have been no
reports of these mutations pre-existing in cell lines or patients
before anti-EGFR therapy10–12,21,36.
Although the analysis of clinical samples was retrospective, the
results are intriguing and provide an interesting hypothesis for
further studies. Overall, our data suggest that in populations of
CRC cells, resistance to EGFR blockade is accompanied by
multiple waves of clonal expansion and can ultimately lead to the
emergence of clones carrying multiple mutations. This process is
reminiscent of the multistep progression model associated with
the clinical evolution of colorectal tumours. Accordingly, we
propose that ‘environmental’ and ‘drug’ pressures analogously
affect the genetic evolution of CRC cells.
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Figure 5 | Emergence of RAS and EGFR ECD mutations in CRC cell populations. RAS and EGFR mutation frequencies were measured by ddPCR
and are indicated for LIM1215 cells cultured in low-serum, chemotherapy, chemotherapy plus cetuximab and cetuximab-only conditions. R1 and R5 cetux
indicate two resistant populations of LIM1215 generated independently. Cetux, cetuximab.
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Methods
Patient samples and clinical characteristics. We included patients with
histologically confirmed metastatic CRC treated with anti-EGFR-based therapy
recruited at Hospital del Mar (Barcelona, Spain) between January 2013 and January
2016, Ospedale Niguarda (Milano, Italy) between March 2011 and May 2014,
Fondazione IRCCS Istituto Nazionale dei Tumori (Milano, Italy) between July
2012 and October 2013, and Citta` della Salute e della Scienza, San Giovanni Battista
Hospital (Torino, Italy) between August and October 2013. Protocols through
which tumour specimens were obtained were the following: Hospital del Mar
(protocol CEIC-2012/4741/I); Ospedale Niguarda (protocols 1014/09 and
194/2010); Fondazione IRCCS Istituto Nazionale dei Tumori (protocol INT 73/12);
and Citta` della Salute e della Scienza, San Giovanni Battista Hospital (protocol
PROFILING). All protocols were approved by the local Ethics Committee of each
institution. All participating patients signed written informed consent. All included
patients had acquired resistance to anti-EGFR therapy defined as disease pro-
gression following (i) complete response or partial response or (ii) stable disease for
more than 16 weeks, and at the time of progression, a RAS (KRASþNRAS) and/or
EGFR mutation was detected. Response was evaluated according to the RECIST
version 1.1 (ref. 37). PFS was defined as the time from anti-EGFR treatment start to
disease progression or death. One patient (#23) received a first course of 6 months
with anti-EGFR and irinotecan, and a subsequent course of 6 weeks with
anti-EGFR in combination with an insulin-like growth factor receptor type I
inhibitor. Concerning Hospital del Mar working group, biological samples were
obtained from Parc de Salut Mar Biobank (MARBiobanc). Baseline pretreatment
mutation analysis in tissue (primary tumour or metastasis) was carried out using
the standard of care procedures for patients with mCRC considered for anti-EGFR
treatment under the local direction of the clinical Institutions that participated in
the study. Standard Sanger sequencing and pyrosequencing were used for
pretreatment mutation analyses. Hospital del Mar used the therascreen RAS RGQ
PCR Kit (Qiagen, Ref 874011) and RAS Extension Pyro Kit (Qiagen, Ref 971590).
San Giovanni Battista Hospital used the PYROMARK Q96 ID kit (Diatech
Pharmacogenetics, cod. UP032). Ospedale Niguarda and IRCCS Istituto Nazionale
dei Tumori used Sanger Sequencing according to the protocol described in
refs 38,39.
For very-high-sensitivity pretreatment analyses, RAS and EGFR mutations at
baseline were analysed in tissue samples. Mutations in exons 2, 3 and 4 from
KRAS and NRAS and exon 12 of EGFR were analysed by pyrosequencing in the
NGS 454 GS Junior platform (Roche Applied Science). Library preparation was
performed with the ONCOGENBASIC-S1 KIT (Seqplexing, Valencia, Spain) to
simultaneously amplify BRAF (exon 15), KRAS (exons 2, 3 and 4) and NRAS
(exons 2, 3 and 4). To analyse EGFR ECD, two amplicons were generated using two
primer sets (Supplementary Table 3). Processed and quality-filtered reads were
analysed using the GS Amplicon Variant Analyzer software version 2.5p1 (Roche).
Mutations detected by NGS were confirmed by competitive allele-specific TaqMan
PCR (CAST-PCR, Applied Biosystems Ref 4465804). The following individual
assays were used: KRAS p.Q61H Hs00000137_mu; KRAS p.Q61L Hs00000135_mu;
NRAS_p.G12S—Hs00000793_mu; and NRAS_p.Q61K—Hs00000804_mu. All
samples were also screened by the PGM Ion Torrent platform using the OncoMine
Focus 318 DNA Assay (Life Technologies, Ref A28548G) to prepare the libraries.
RAS and EGFR mutations at the time of progression were analysed in both
tissue and plasma samples. RAS mutations in tissue samples were determined by
the Therascreen RAS RGQ PCR KIT for KRAS codons 12 and 13, and RAS
Extension Pyro Kit (Qiagen) for KRAS exons 3 and 4 and NRAS (exons 2, 3 and 4)
as described above. EGFR exon 12 in tissue samples was analysed by Sanger
sequencing to uncover EGFR ECD mutations as described previously11. Plasma
samples only were obtained from Ospedale Niguarda, Citta` della Salute e della
Scienza—San Giovanni Battista Hospital and Fondazione IRCCS Istituto Nazionale
dei Tumori, and assessed by ddPCR as described in the Methods section.
Automated ctDNA isolation from plasma samples. ctDNA was extracted from
1ml plasma using the Maxwell RSC ccfDNA Plasma Kit with the automated
Maxwell RSC Instrument (Promega) according to the manufacturer’s instructions.
Lentivirus packaging. The lentiviral barcode library was packaged in HEK-293T
cells using 10mg of the Cellecta 13K 13K barcode library plasmid and
second-generation packaging vectors pCMV-dR8.74 (6.5 mg), pRSV-REV (2.5 mg)
and pMD2-VSV-G (3.5 mg) per 10 cm dish (10 dishes total) following the standard
protocol for transfection by calcium phosphate precipitation40. Media were
replaced after 16 h, DNAse treated (1Uml 1) 24 h post replacement and
collected/filtered 24 h later for virus collection.
Cell models. The LIM1215 parental cell line41 was obtained from Prof Robert
Whitehead, Vanderbilt University, Nashville, with permission from the Ludwig
Institute for Cancer Research Ltd (New York, NY) and were cultured in
RPMI-1640 medium (Invitrogen) supplemented with 10% FBS and insulin
(1mgml 1); OXCO-2 cell lines were a kind gift from Dr V. Cerundolo in
March 2010 (Weatherall Institute of Molecular Medicine, University of Oxford,
UK), and were cultured in Iscove’s medium (Invitrogen) supplemented with 10%
FBS. Both LIM1215 and OXCO-2 are mismatch repair deficient (microsatellite
unstable) as confirmed by the MSI Analysis System, Version 1.2 kit (Promega). The
authentication of each cell line was completed by Cell ID System and by Gene Print
10 System (Promega), through short tandem repeats (STR) at 10 different loci
(D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and
amelogenin). Amplicons from multiplex PCR products were separated by capillary
electrophoresis (3730 DNA Analyzer, Applied Biosystems) and analysed using
GeneMapperID software from Life Technologies. These STR profiles were
cross-validated with the available STR from other cell bank databases. All cell lines
were tested and resulted negative for mycoplasma contamination with Venor GeM
Classic kit (Minerva Biolabs).
Generation of barcoded founder populations. LIM1215 parental CRC cells were
used to make the founder population. In all, 1 106 cells were transduced at a
multiplicity of infection of 0.1 with 5 mgml 1 polybrene. Media were changed 24 h
post transduction. Puromycin (1mgml 1) was added at 96 h post transduction to
select cells with lentiviral integration and continued for 96 h.
Serum-deprived and drug-treated cells. For the serum deprivation experiment,
the barcode founder LIM1215 cells were cultured in RPMI supplemented with 1%
FBS for 4 months. Cells were collected at 4 months for preparation of gDNA. For
chemotherapy experiments, LIM1215 cells were cultured in their respective media
supplemented with 5% serum and treated with FOLFIRI (10 mM 5FUþ 100 nM
SN-38, active metabolite of irinotecan) alone or in combination with cetuximab
(350 nM). To parallel the chemotherapy schedule administered to human patients,
cells were treated with FOLFIRI for four cycles of 2 days each; each cycle is
separated from the next one by 12 days. At the end of the fourth cycle of
chemotherapy, cells were allowed to repopulate in absence of drugs, and
growing cells were then collected (total: 2.5 months). Instead, in combinatorial
FOLFIRIþ cetuximab setting, cetuximab was continuously maintained throughout
the treatment period until a resistant population emerged (5 months). gDNA was
extracted using the ReliaPrep gDNA Tissue Miniprep System (Promega).
LIM1215 and OXCO-2 cetuximab-resistant cells were described
previously11,20,30. gDNA was extracted using the Wizard SV Genomic DNA
Purification System (Promega). For generation of barcoded cetuximab-resistant
cells, the barcode founder population was treated continuously with 350 nM
cetuximab in their media supplemented with 5% serum forB6 months. Cells were
screened for resistance to cetuximab starting at B1 month and at 1-month
increments until resistance was achieved. Cells were saved for gDNA analysis and
aliquots were preserved in liquid nitrogen at each screening.
For limiting cell dilution, the resistant pools were diluted such that they are
plated at 1 cell per well (5 cells per ml) in a 96-well tissue culture plate. Wells
are screened for single colonies, colonies consolidated, and screened for barcodes
and/or mutations. gDNA was extracted from limiting cell dilution clones using
Wizard SV 96 Genomic DNA Purification System (Promega) and were analysed
for the barcode sequence and/or mutations in KRAS (exons 2, 3 and 4), NRAS
(exons 2 and 3) and EGFR (exon 12) with Sanger sequencing using automated
sequencing by ABI Prism 3730 (Applied Biosystems). Primer sequences for KRAS,
NRAS and EGFR have been described previously11,20,30. The barcode primer
sequences were designed by Cellecta based on the lentiviral vector cassette and are
listed in Supplementary Table 3.
Fluorescence in situ hybridization analysis. To measure EGFR gene copy
numbers, dual-colour fluorescence in situ hybridization (FISH) analysis was
performed as previously described20. More in details: dual-colour FISH analysis
was performed on metaphase chromosomes and interphase nuclei obtained
from the parental and resistant clones of LIM1215 following the standard
procedures. To identify possible alterations in EGFR gene copy number,
EGFR(7p12)/CEN7q(7q11.21) probes (Abnova, Catalog Number FG0005) labelled,
respectively, with Texas Red and fluorescein isothiocyanate were used. Probes and
target DNA were co-denatured for 5min at 75 C and then hybridized overnight at
37 C. Slides were washed with post-hybridization buffer (DakoGlostrup) at 73 C
for 5min and counterstained with 4,6-diamino-2-phenylindole (DAPI II; Vysis).
FISH signals were evaluated with a Zeiss Axioscope Imager. Z1 (Zeiss) equipped
with single and triple band pass filters. Images for documentation were captured
with a charge-coupled device camera and processed using the MetaSystems Isis
software.
Barcode NGS and analysis. gDNA collected from the barcoded cells during the
cetuximab resistance protocol were prepared using phenol:chloroform extraction
and ethanol precipitation. The extracted DNA was quantitated using the Qubit
dsDNA BR Assay (Invitrogen). A unit of 150 ng of gDNA was used to amplify the
barcode sequence and generate the amplicon library using Phusion High-Fidelity
DNA Polymerase (New England Biolabs). For the cetuximab resistance
experiments, the primers (HPLC purified) used were generated from the lentiviral
vector cassette sequence and contain the adaptors specific for 454 GS FLX
Titanium Lib-L sequencing system (Roche) (Supplementary Table 3). The forward
primer contains a unique multiplex identifier allowing samples to be pooled for the
sequencing reaction and sorted post sequencing. The PCR products were size
selected with the E-Gel Size Select Gels (Life Technologies) and purified twice using
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Agencourt AMPure XP as described in the 454 Sequencing Amplicon Library
Preparation Method Manual (Roche Diagnostics). Purified products were screened
for quality using the 2100 Bioanalyzer with the High Sensitivity DNA kit (Agilent
Technologies) and quantitated using the Qubit dsDNA HS Assay (Invitrogen).
Individual amplicons were diluted to 1 109 molecules per ml, then samples to be
sequenced together were pooled (five samples per pool) and diluted to 1 107
molecules per ml to generate the amplicon library. The library was amplified and
prepared for sequencing using the emulsion PCR large volume kit for Lib-L. Two
libraries containing five samples each were loaded into two lanes of the PicoTiter
Plate as described in the Sequencing Method Manual (Roche Diagnostics).
Analysis was performed considering that every sequence should include a linear
structure of two 32 bp-long primers surrounding the 40 bp random barcode. We
used BLAT42 to identify the position of this structure and applied a custom script
to extract it for further analysis; reads that did not match this sequence were
discarded. To lower the noise due to sequencing error, we evaluated the distance
between every barcode by applying an all-against-all BLAST43 alignment. We
considered as the same barcode those sequences displaying no more than one
mismatch with each other. Finally, we counted the occurrence of each barcode
sequence.
Mutational profile by NGS. Libraries were prepared with Nextera Rapid Capture
Custom Enrichment Kit (Illumina Inc), according to the manufacturer’s protocol.
Preparation of libraries was performed starting from 100 ng of gDNA. gDNA was
fragmented using transposones, adding simultaneously adapter sequences. Purified
tagmented gDNA was used as template for subsequent PCR to introduce unique
sample indexes. The size distribution of the DNA fragments was assessed using the
2100 Bioanalyzer with the High Sensitivity DNA assay kit (Agilent Technologies).
Equal amounts of DNA libraries were pooled and subjected to targeted panel
hybridization capture as previously described13. Libraries were then sequenced
using the Illumina MiSeq sequencer (Illumina Inc.).
FASTQ files generated by Illumina MiSeq were preprocessed to remove adapter
sequences and bases with a Phred quality score o20. They were mapped to the
human reference, assembly hg19, using BWA-mem algorithm44. PCR duplicates
were then removed using the RMDUP command of SAMtools package45. We used
a custom pipeline for NGS, to call somatic variations when supported by at least
1% allelic frequency and 5% Fisher’s test significance level. Mutational discovery
analyses were performed according to previously published methods13 comparing
each of the different time points with parental samples. Mutations were annotated
by a custom script printing out gene information, number of normal and mutated
reads, the allelic frequencies and the variation effect.
Droplet digital PCR analysis. Plasma circulating ctDNA from CRC patients and
gDNA from CRC cells were amplified using ddPCR Supermix for Probes (Bio-Rad)
using KRAS, NRAS (PrimePCR ddPCR Mutation Assay, Bio-Rad) and EGFR
(custom-designed assays) for point mutations. Catalogue numbers and
custom-designed probe sequences are indicated in Supplementary Table 5. ddPCR
was then performed according to the manufacturer’s protocol and the results
reported as percentage or fractional abundance of mutant DNA alleles to total
(mutant plus WT) DNA alleles. A volume of 8–10 ml of DNA template was added
to 10ml of ddPCR Supermix for Probes (Bio-Rad) and 2 ml of the primer/probe
mixture. Droplets were generated using the Automated Droplet Generator
(Auto-DG, Bio-Rad), where the reaction mix was added together with Droplet
Generation Oil for Probes (Bio-Rad). Droplets were then transferred to a 96-well
plate (Eppendorf) and then thermal cycled with the following conditions: 5min at
95 C; 40 cycles of 94 C for 30 s; 55 C for 1min followed by 98 C for 10min
(Ramp Rate 2 C s 1). Droplets were analysed with the QX200 Droplet Reader
(Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was
performed based on positive and negative controls, and mutant populations
were identified. The ddPCR data were analysed with QuantaSoft analysis software
(Bio-Rad) to obtain fractional abundance of the mutant DNA alleles in the
WT/normal background. The quantification of the target molecule was presented
as number of total copies (mutant plus WT) per sample in each reaction. Fractional
abundance is calculated as follows: FA %¼ ((Nmut/(NmutþNwt)) 100),
where Nmut is number of mutant events and Nwt is number of WT events per
reaction. ddPCR analysis of normal control (from cell lines) and no DNA template
controls were always included. Samples with positive events that were too low were
repeated at least twice in independent experiments to validate the obtained results.
Sensitivity is calculated as follows: sensitivity¼ ((1/(C/2)) 100, where C is the
number of total target copies per ddPCR reaction (mutant plus WT). The number
of mutated events required to be detected to call a sample positive for that
particular target is two. If the fractional abundance from those two events is below
the calculated sensitivity in the reaction, then it is a false positive.
Cell viability assays. Cetuximab was obtained from the Pharmacy at Grande
Ospedale Metropolitano Niguarda, Milan, Italy. LIM1215 cells were seeded
(2 103 per well) in 100 ml medium in 96-well culture plates. After 24 h, 100ml of a
serial dilution of cetuximab was added to the cells, and medium-only wells were
included as controls. Plates were incubated at 37 C in 5% CO2 for 6 days,
after which cell viability was assessed by ATP content using the Cell Titer-Glo
Luminescent Assay (Promega). Measurements were recorded using the Spark
Microplate Reader (Tecan). Treated wells were normalized to untreated. Data
points represent mean±s.d. of three independent experiments performed with
three technical replicates.
Clonogenic assays. LIM1215 cells were seeded (4 103 per well in 24-well
culture plates). After 24 h, a serial dilution of cetuximab was added to the cells,
and medium-only in control wells. Four technical replicates were plated per
experiment. Plates were incubated at 37 C in 5% CO2 for 8 days, after which cells
were fixed with 4% paraformaldehyde and stained with 1% crystal violet-methanol
solution (Sigma-Aldrich).
Immunoblot analysis. Total cellular proteins were extracted by solubilizing the
cells in cold EB buffer (50mM HEPES (pH 7.4), 150mM NaCl, 1% Triton X-100,
10% glycerol, 5mM EDTA and 2mM EGTA; all reagents were from
Sigma-Aldrich, except for Triton X-100 from Fluka) in the presence of 1mM
sodium orthovanadate, 100mM sodium fluoride and a mixture of protease
inhibitors (pepstatin, leupeptin, aprotinin, soybean trypsin inhibitor and
phenylmethylsulfonyl fluoride). Extracts were clarified by centrifugation, and
protein concentration was determined using BCA protein assay reagent kit
(Thermo). Western blot detection was performed with enhanced chemilumines-
cence system (GE Healthcare) and peroxidase-conjugated secondary antibodies
(Amersham). Chemoluminescent signal was acquired by the LAS4000 Image
Reader (Fujifilm). The following primary antibodies were used for western blotting
(all from Cell Signaling Technology, except where indicated): anti-phospho p44/42
ERK (Thr202/Tyr204); anti-p44/42 ERK; anti-phospho-AKT (Ser473); anti-AKT;
anti-phospho EGFR (Tyr1068, Abcam); anti-EGFR (clone13G8, Enzo Life
Sciences); and anti-vinculin (Sigma-Aldrich). All the antibodies were diluted
1:1,000 except for total EGFR (1:100) and vinculin (1:2,000). Full-length blot can be
viewed in Supplementary Fig. 6.
Statistical analysis. In patients, Fisher’s exact test was used to assess the
correlation between RAS/EGFR mutations and response to treatment. w2-analysis
and the Cox proportional regression model were used for survival analyses. Hazard
ratios and 95% CIs were calculated. We estimated survival curves using the
Kaplan–Meier method. We analysed PFS after anti-EGFR treatment according to
EGFR mutations (including cases with co-existing RAS mutations) and RAS
mutations (excluding cases with co-existing EGFR mutations). Patients for which
the radiologic data were not available were censured at the last follow-up. All
statistical tests included are appropriate and the assumption of normality for the
group is accepted with a Shapiro–Wilk test of 0.94 (P¼ 0.55). The variances are
similar with a Levene value of F¼ 0.772 (P¼ 0.388). All the statistical tests were
conducted at the two-sided 0.05 level of significance. Statistical analysis was
performed with the SPSS Statistical Software (SPSS, Inc., Chicago, IL, USA).
Statistical analysis of the cell viability assays was performed using the software
GraphPad PRISM 6.0. The P value was calculated by unpaired two-tailed Student’s
t-test. All values reported in the proliferation assays correspond to means±s.d. of
at least three independent experiments, each with three experimental replicates.
Data availability. NGS data for this study have been deposited in the European
Nucleotide Archive (ENA) with the accession code PRJEB15863. The remaining
data are available within the article and its Supplementary Information file, or
available from the authors upon request.
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